Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Investment Bank TD Cowen Revises Price Targets for Bitcoin (BTC)! Bear or Bull? Here are the Details

Investment Bank TD Cowen Revises Price Targets for Bitcoin (BTC)! Bear or Bull? Here are the Details

BitcoinSistemiBitcoinSistemi2026/10/08 18:12

Bitcoin, one of the most closely followed assets by investors in the cryptocurrency market, continues to search for direction, with both short-term and long-term predictions emerging.

At this point, the latest forecast comes from investment bank TD Cowen. While TD Cowen maintains its optimism regarding Bitcoin’s long-term outlook, it paints a more cautious picture for Strategy shares.

Long-Term Expectations for Bitcoin are Strengthening!

Lance Vitanza, Managing Director and Senior Analyst of Digital Asset Strategies at TD Cowen, stated that Bitcoin’s position is increasingly shifting for institutional investors. According to Vitanza, institutions are no longer simply debating whether or not to invest in Bitcoin, but rather which financial instruments to use to enter the cryptocurrency market.

In this context, Vitanza predicts that Bitcoin could perform at an average annual rate of 20 to 30 percent in the long term.

Vitanza stated that, according to TD Cowen’s current projections, Bitcoin is expected to reach $109,000 by the end of 2026, $132,750 by the end of 2027, and $280,000 by the end of 2029.

In this context, TD Cowen states that he has raised his Bitcoin price prediction to $109,000 by the end of 2026 and $280,000 by 2029.

TD Cowen’s Bitcoin price predictions have changed significantly throughout the year, with the bank lowering its end-2026 Bitcoin forecast from $140,000 to around $100,000 in June.

TD Cowen remains cautious about Strategy shares despite the improvement in Bitcoin expectations. The bank stated that it is maintaining its price target for Strategy at $260, citing as justification the fact that the capital increases the company is undertaking to finance its Bitcoin purchases are limiting the share of existing shareholders.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53